# Epithalon FAQ: Common Questions on Epitalon Research

> Frequently asked questions on Epithalon and Epitalon — telomerase, dosage, side effects, regulatory status, and the research record. Direct answers with citations from published studies.

Twenty-six questions addressed directly, each with a citation-grounded answer. Where the evidence is thin, that is the answer.

## Epithalon Side Effects Observed in Research

What are the side effects of Epithalon? No serious adverse events have been reported in any published preclinical or observational human study. The rodent longevity protocols running monthly subcutaneous administrations for the animals' full lifespans documented no toxic effects [4, 14, 16]. The retinitis pigmentosa clinical series in 162 patients reported positive clinical outcomes in approximately 90% of cases with parabulbar administration and no adverse events [8]. The 2007 Korkushko et al. study concluded Epitalon is suitable for geriatric clinical practice partly on the basis of efficacy and absence of adverse effects [7].

Side Effects of Epithalon Observed in Research: Mild injection-site reactions are noted in some reports with subcutaneous administration. No systemic adverse events appear in the published literature.

What is notably absent: long-term controlled safety data in humans. The theoretical concern associated with reactivating telomerase in somatic cells — the same enzyme that cancer cells upregulate to maintain their division — has not been evaluated in long-term human toxicity studies. The 2025 Al-dulaimi cell-line study found that Epitalon activated the ALT pathway (not telomerase) in cancer cell lines while activating telomerase in normal cells [2], which is mechanistically interesting but does not resolve the theoretical concern for in vivo use.

## Regulatory and Legal Questions

What Is the Regulatory Status of Epitalon? Epithalon (Epitalon) is not approved by the FDA for any therapeutic indication in the United States. It is classified as a research chemical. Injectable compounded forms were placed in FDA Category 2 (non-503A Bulks List) as of 2024–2025, restricting preparation by compounding pharmacies without FDA approval. A PCAC (Pharmacy Compounding Advisory Committee) review hearing on potential reclassification is scheduled for 2026.

Is Epitalon approved by the FDA? No — not for any therapeutic indication. The FDA Category 2 designation means compounding pharmacies may not prepare it for office stock or prescription under the 503A framework without meeting additional regulatory criteria.

Is Epitalon legal to purchase? In most jurisdictions outside Russia, Epithalon is classified as a research chemical. Oral/sublingual formulations occupy a gray regulatory space in many markets. In Russia, peptide bioregulators including the Epithalamin extract have a longer history of clinical use and regulatory acceptance. Athletes should assume prohibited status under WADA's S0 Non-Approved Substances category, which covers any pharmacological substance not approved by a regulatory authority for human therapeutic use — a category that includes Epitalon.

## Definitions and Terminology

What is Epitalon peptide? Epithalon (Epitalon) is the synthetic tetrapeptide Ala-Glu-Asp-Gly (AEDG), molecular weight approximately 390 Da, derived from the amino acid composition of Epithalamin (bovine pineal gland extract) and confirmed present in human pineal tissue [17]. It is studied primarily as a telomerase activator and pineal bioregulator.

What is the difference between Epitalon and Epithalon? Both names refer to the identical synthetic tetrapeptide Ala-Glu-Asp-Gly. 'Epitalon' is the transliteration used in Russian scientific literature; 'Epithalon' is the variant adopted in English-language markets and carries higher tracked English search volume. The compound's chemistry, mechanism, and research record are identical under both spellings. See the [Epitalon vs. Epithalon spelling](/#epitalon-vs-epithalon) note on the overview page.

## Mechanism and Efficacy Questions

What does Epithalon peptide do? Epithalon activates telomerase by upregulating hTERT gene expression, extending telomere length in dividing cells [1, 2]. It also modulates pineal melatonin secretion via AANAT/pCREB pathways [17], activates antioxidant defense genes through the Nrf2/Keap1 axis [15], and has shown oncostatic effects in rodent tumor models [9, 10]. See the [frequently asked questions](/faq) section and the research page for mechanism detail.

What does Epitalon peptide do in research? Upregulates telomerase reverse transcriptase (TERT) expression; extends telomere length in dividing cells; reduces reactive oxygen species; modulates melatonin secretion via pineal gland peptide bioregulation [1, 2, 15, 17].

How does Epitalon activate telomerase? Proposed mechanism: upregulates TERT gene expression, increasing telomerase enzyme availability in somatic cells that normally silence the gene, thereby slowing telomere shortening associated with cellular senescence [1, 2]. The 2025 Al-dulaimi study confirmed hTERT upregulation up to 12-fold in cancer cell lines and up to 26-fold telomerase activity increase in normal HMEC cells [2].

Can Epitalon extend telomeres? In vitro: yes. Statistically significant telomere elongation from 2.4 kb to up to 8 kb was demonstrated in four human cell lines at 0.1–1.0 μg/mL [2]. Telomere elongation was also confirmed in human fetal fibroblasts in 2003 [1] and averages 33.3% in human lymphocytes across studies per the 2025 Araj review [17]. In vivo human data is not available.

Does Epitalon really work for anti-aging? Multiple rodent longevity studies (St. Petersburg Gerontology Institute) show 12.3–16% lifespan extension; telomere elongation is confirmed in human cell lines [2]. No randomized controlled trial in humans exists for aging or longevity endpoints. See the [Epitalon anti-aging studies](/research#anti-aging) section.

## Specific Application Questions

What are the benefits of Epithalon? Studied for telomerase activation, telomere elongation, antioxidant effects, circadian rhythm normalization via pineal/melatonin pathway, oncostatic properties in rodent models, neurogenic gene upregulation, and senescence marker reduction in stem cells [1, 2, 4, 5, 9, 11, 13, 17].

What is Epitalon peptide used for? Research applications include telomere biology, aging/longevity models, circadian rhythm normalization, neuroendocrine regulation, oncostatic effects in rodent and cell-culture studies, retinal cell protection, and neurogenic differentiation studies [1, 2, 4, 5, 9, 15, 17].

Does Epithalon affect melatonin? Yes — studied as a pineal gland bioregulator; Epitalon stimulated evening melatonin synthesis in senescent rhesus macaques [5], normalized circadian cortisol rhythms [5], and restored nighttime melatonin amplitude in elderly human subjects with baseline insufficiency in a bidirectional, modulatory manner [6, 7].

Can Epitalon improve sleep? Via melatonin pathway normalization, studies in elderly subjects report improved circadian rhythm markers and melatonin amplitude restoration [5, 6, 7]. Direct sleep-outcome measurements using validated instruments have not been published. See the [Epithalon and Sleep](/research#sleep-melatonin) section.

Is Epitalon studied for cancer? Rodent studies report reduced incidence of mammary tumors in HER-2/neu transgenic mice [9], reduced colon tumor incidence and multiplicity in chemically induced models [10], and complete prevention of metastases in C3H/He mice at low-dose long-term administration [16]. All oncostatic findings are preclinical. Epitalon is not a cancer treatment; these findings describe what was observed in animal models under experimental conditions.

What does Epitalon do for the brain? Cellular and animal models suggest enhanced neurogenic marker expression (Nestin, GAP43, β-Tubulin III, Doublecortin — 1.6–1.8 fold increase) [11], chromatin decondensation and ribosomal gene activation in aged lymphocytes [12], and cholinesterase activity increases of 10–25% in neuroblastoma cells [17].

How does Epitalon compare to other longevity peptides? Among bioregulator peptides (Thymalin, Cortagen, Vilon), Epitalon has the most peer-reviewed telomere-focused data. Unlike GHK-Cu (primarily tissue repair and collagen) or endocrine-signaling peptides, Epitalon's primary studied mechanism is telomerase activation rather than tissue repair or receptor-mediated signaling [17].

Is Epithalon safe to take? Preclinical studies report a low acute toxicity profile across rodent and Drosophila models [3, 4, 14, 16]. No serious adverse events are documented in published human observational studies [7, 8]. Long-term controlled safety data in humans is absent from the published literature. The theoretical concern about telomerase reactivation in somatic cells has not been evaluated in human safety trials.

## History and Development

Who developed Epitalon? Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology synthesized Epitalon from Epithalamin's active fraction, beginning with Epithalamin research in the 1970s–1980s and first describing the synthetic tetrapeptide as a telomerase activator in the early 2000s [1]. The longevity rodent studies were conducted by Khavinson and Anisimov at the same institute [3, 4, 14].

What is the difference between Epithalamin and Epithalon? Epithalamin is a crude polypeptide extract of bovine pineal glands, studied since the 1970s at the St. Petersburg Institute; Epithalon (Epitalon) is the synthetic tetrapeptide Ala-Glu-Asp-Gly isolated from Epithalamin's active fraction. The synthetic version allows precise dosing and purity control [17]. See the [Epithalamin vs. Epithalon section](/research#epithalamin) for full detail.

What is the Epithalon dosage used in research protocols? Published protocols vary by context: 1.0 μg/mouse subcutaneous (5 days/month) in rodent longevity studies [4], 0.1 μg/mouse subcutaneous (5 days/week) in oncostatic studies [16], 5.0 μg parabulbar (10 consecutive days) in the retinitis pigmentosa human series [8], and 0.1–1.0 μg/mL in vitro in cell-line studies [2]. See the [Epithalon dosage in the research literature](/dosage) for the full range.

How long is the Epithalon cycle? Rodent protocols: 5 consecutive days per month, repeated monthly [4, 14]. Retinitis pigmentosa clinical series: 10 consecutive days as a single course [8]. Russian longevity observational protocols described in secondary literature: 10–20 day cycles, 1–2 times per year [17].

How long does Epithalon take to work in research models? Telomerase activity was detectable within days in cell-line studies [1, 2]. Circadian normalization effects appeared within weeks in animal models [5, 7]. Human timing data outside the retinitis pigmentosa series is not published.

What is the half-life of Epitalon? Formal human pharmacokinetic data is absent. Estimated plasma half-life of approximately 30 minutes based on tetrapeptide clearance kinetics; downstream transcriptional and epigenetic effects may persist beyond plasma clearance. No validated published human half-life figure. See the [Epitalon half-life and pharmacokinetics](/dosage#half-life) section.

---

Gilt scrollwork around a twenty-five year literature — the Epithalon record read leaf by leaf, cited to the source, and held by no clinic and no vendor.